ANRO Alto Neuroscience Inc: Enterprise Value-to-Revenue Ratio

Official company branding of Alto Neuroscience (ANRO)

The price-to-sales trajectory of Alto Neuroscience, Inc. (ANRO) reflects current dynamics, where the 0.00 mark indicates the market valuation level. Alto Neuroscience, Inc. (ANRO) is scaling a unique AI system as it moves toward final drug trials. The biotech firm is developing personalized treatments for psychiatric disorders in the US. Its leadership is driven by the implementation of a brain biomarker analysis platform to combat schizophrenia and depression.

ANRO (Alto Neuroscience) Enterprise Value-to-Revenue Ratio history from 11/23/2025 to 11/20/2026

ANRO (Alto Neuroscience, Inc.): analytical breakdowns and indicator data

- current quotes and average value forecast:
Fundamental company valuation:ANRO, Alto Neuroscience
Product sample of Alto Neuroscience Corp

This indicator determines the enterprise value of the business minus net debt, comparing it to annual sales volume to identify fundamental valuation imbalances. The current EV/Sales market multiple stands at 0.00, reflecting market expectations for the capitalization of Alto Neuroscience, Inc. (ANRO) within the context of developing personalized AI-driven drugs for the therapy of psychiatric disorders.